Jim Cramer
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced […]
Read More
Jim Cramer blasts the prospect of a Humana-Cigna deal — it could never be approved by regulators
Jim Cramer urged Humana (HUM) not to pursue a merger with rival health insurer Cigna (CI), questioning the merits of a potential business combination and the likelihood of it passing U.S. antitrust review. Cigna and Humana could reach an agreement on a stock-and-cash transaction by the end of the year, The Wall Street Journal reported […]
Read More
Jim Cramer knocks down a new analyst sell rating on a medtech stock as shortsighted
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1. Wall Street was mixed Monday after the Dow , the S & P 500 and the Nasdaq finished higher for the fourth straight week. With the last trading day […]
Read More
Amazon adds a new reason to get and keep Prime: member discounts on health-care services
Amazon (AMZN) said on Wednesday that it’s offering Prime members a discount on its new health-care service — another perk that should help bring more people into the online retailer’s ecosystem. The One Medical service, which typically costs $199 annually, will be available to Prime subscribers for $9 a month or $99 per year. It […]
Read More
The sell-off in Humana is overdone after strong earnings. Jim Cramer says buy the stock
The post-earnings decline in Humana (HUM) shares Wednesday was overdone, providing investors an opportunity to add to their positions in the Medicare Advantage-focused health insurer. The Club holding remains on solid ground after delivering a top- and bottom-line beat in the third quarter. Revenue for the three months ended Sept. 30 rose 15.9% to $26.42 […]
Read More
Below are 2 stocks Jim Cramer is ‘most worried about’ and 1 name that he likes
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Conference” livestream at 10:20 a.m. ET. This is a recap of Monday’s critical moments. 1. Wall Avenue noticed a major bounce again Monday, with the Dow leading the way up around 1%. A rally in tech stocks was also supporting the S & […]
Read More
Jamie Dimon’s stock-moving trades show why investors should track CEOs’ buying and selling
For the first time in nearly two decades running JPMorgan Chase, CEO Jamie Dimon will voluntarily sell stock in the bank. The disclosure, in a securities filing Friday, detailed next year’s planned sales — pressuring JPMorgan (JPM) shares and the Dow Jones Industrial Average and highlighting why tracking trades made by executives involving the companies […]
Read More
We had a busy week of trades in an oversold market. Here’s the day-by-day breakdown
Elevated bond yields and geopolitical uncertainty continued to be negative for stocks this week as the overall market moved into oversold territory. However, that set us up to put cash to work and make four small buys as our discipline mandates. We also upgraded one of our tech giants after it reported a stellar quarter […]
Read More
Meta sued by 42 attorneys typical for addictive functions focusing on little ones
A bipartisan team of 42 lawyers typical is suing Meta more than addictive options aimed at children and teens, the AGs announced Tuesday. The assistance from so a lot of point out AGs of different political backgrounds implies a major lawful challenge to Meta’s business enterprise. Meta is now experiencing many lawsuits on this issue […]
Read More
We’re buying more of this life sciences stock after an earnings-driven decline
The stock is under pressure in early trading due to uncertainty around the recovery in a key business. Source
Read More